Drug details

Tabrecta (capmatinib tablets)

type of MET Tyrosine Kinase Inhibitors

Tabrecta (capmatinib) is a kinase inhibitor used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

This drug may have the following side effects:

• nausea,
• vomiting,
• fever,
• shortness of breath,
• weight loss,
• cough
• constipation,
• back pain,
• fatigue,
• swelling of extremities,
• diarrhea, and
• decreased appetite,
• non-cardiac chest pain,

The following drugs are related to Tabrecta, either as a replacement or used together:

• Abraxane (albumin-bound paclitaxel for injectable suspension)
• Gilotrif (afatinib tablets, for oral use)
• Alimta (pemetrexed)
• Alymsys (bevacizumab-maly injection)
• Tecentriq (atezolizumab injection)
• Avastin (bevacizumab)
• Zykadia (ceritinib hard-gelatin capsules)
• Xalkori (crizotinib)
• Cyramza (ramucirumab solution for intravenous infusion)
• Taxotere (docetaxel for injection)
• Imfinzi (durvalumab injection)
• Tarceva (erlotinib)
• Iressa (gefitinib)
• Gemzar (gemcitabine hcl)
• Keytruda (pembrolizumab for injection)
• Zepzelca (lurbinectedin for injection)
• Opdivo (nivolumab injection)
• Tagrisso (osimertinib tablets)
• Retevmo (selpercatinib capsules)
• Tepmetko (tepotinib tablets)